Connect Biopharma Holdings Limited (CNTB) News
Track canonical SquawkNews coverage tagged to CNTB, Connect Biopharma Holdings Limited. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 17 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Connect Biopharma drops after Phase 2 rademikibart endpoint miss
Connect Biopharma plunged after Phase 2 Seabreeze missed the primary endpoint for rademikibart in asthma, despite halving ED/unscheduled visits and improving lung function as a secondary endpoint.
EARNINGS | Sep 21, 2026, 11:28 AM UTC
L
CNTB: Rapid FEV1 improvement and strong health economics support phase III plans for acute asthma
Seabreeze asthma data showed rapid, significant lung function improvement and validated prior findings, supporting phase III advancement. U.S. claims data reveal a large, economically significant acute asthma market, whi
NEWS | Sep 15, 2026, 04:30 PM UTC
L
Connect Biopharma Price Target Maintained With a $10.00/Share by BTIG
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 04:27 PM UTC
L
CNTB: Rapid efficacy and strong economic value support phase III plans for acute asthma treatment
Seabreeze asthma study results confirmed rapid, significant lung function improvement and reduced exacerbations, supporting phase III planning and regulatory engagement. Updated U.S. data reveal a larger market and stron
NEWS | Sep 15, 2026, 04:13 PM UTC
L
CNTB: Rademikibart reduced treatment failure by 66% and improved FEV₁ rapidly in acute asthma
A Phase 2 trial of rademikibart in acute asthma exacerbations showed a 66% reduction in treatment failure versus placebo and rapid, significant FEV₁ improvement, with a favorable safety profile. These results support fur
NEWS | Sep 15, 2026, 01:23 PM UTC
L
CNTB: Rademikibart showed rapid, significant FEV1 improvement and reduced treatment failures in acute asthma
The Seabreeze STAT asthma study showed rademikibart rapidly improved airway function and reduced treatment failures, with a significant FEV1 benefit at day 7. The drug was well-tolerated, and plans are underway to propos
NEWS | Sep 15, 2026, 01:22 PM UTC
L
Connect Biopharma drops as asthma candidate fails in mid-stage trial
Connect Biopharma NASDAQ:CNTB lost nearly 40% in premarket trading on Tuesday after announcing that its lead candidate, rademikibart, failed to reach the primary endpoint in a Phase 2 trial for patients with asthma.The g
NEWS | Sep 15, 2026, 12:11 PM UTC
L
CNTB: Rademikibart shows rapid, sustained efficacy and safety in asthma, COPD, and atopic dermatitis
Rademikibart demonstrated strong efficacy and safety in acute asthma, COPD, and atopic dermatitis, with rapid and sustained lung function improvements and a differentiated safety profile versus dupilumab. Market research
NEWS | Sep 15, 2026, 11:47 AM UTC
L
CNTB: Rademikibart reduced treatment failure by 66% and improved lung function in acute asthma exacerbations
A Phase 2 study showed rademikibart as an add-on for acute asthma exacerbations reduced treatment failure by 66% and improved lung function significantly at Day 7, with a favorable safety profile. Plans are underway for
NEWS | Sep 15, 2026, 11:14 AM UTC
L
Connect Biopharma reports Phase 2 asthma topline: +130 mL FEV1 vs placebo; 66% lower treatment failures
Connect Biopharma reported Phase 2 topline: rademikibart gave a 130 mL greater FEV1 increase vs placebo at Day 7 and a 66% reduction in 28-day treatment failures (not statistically significant for primary endpoint).Key H
REGULATION | Sep 15, 2026, 11:13 AM UTC
L
CNTB - Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
CNTB - Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type
NEWS | Sep 15, 2026, 11:00 AM UTC
L
Connect Biopharma management to present at H.C. Wainwright conference
Connect Biopharma Holdings Limited said company management will present at the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 03, 2026, 08:08 PM UTC
L
CNTB - Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
CNTB - Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 03, 2026, 08:05 PM UTC
L
CNTB Reports Q2 2026 Financial Results
CNTB reports second quarter 2026 financial results and provides business update
EARNINGS | Aug 12, 2026, 08:05 PM UTC
L
Connect Biopharma initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Connect Biopharma with an Outperform rating and $8 price target. Connect Biopharma is a single-asset story built on rademikibart, a next-generation human IgG4 anti-interleukin-4 receptor
EQUITY | Jul 09, 2026, 11:57 AM UTC
M
CNTB: Piper Sandler Initiates
Piper Sandler initiates coverage on Connect Biopharma Hldgs with an Overweight rating and a price target of $7.
EQUITY | Jun 26, 2026, 01:44 PM UTC
M
BDC: BUY @ Citi
Citi initiates BDC with a BUY rating, among other top initiations
EQUITY | Jun 26, 2026, 11:17 AM UTC